FDA declines to approve Summit’s lung cancer drug

This site is intended for healthcare professionals

Summit shares plummet as FDA rejects experimental lung cancer drug

Cecilia Adamou:
Person receiving IV drugs in HARMONi trail for non small cell lung cancer drug from Summit which was rejected

Key Summary:

  • The FDA declined to approve Summit’s ivonescimab with chemotherapy for advanced lung cancer.
  • The agency cited survival data and questioned how well the trial findings applied to US patients.
  • Summit shares closed at $10.50 on 18 November, about 26% below their pre-announcement close.

Summit Therapeutics has suffered a setback in its bid to bring its lead experimental cancer drug to the US after the Food and Drug Administration (FDA) declined approval.

The American drug company had applied to use ivonescimab with chemotherapy in patients with a form of advanced non-small cell lung cancer who had already received treatment targeting an EGFR mutation.

While positive data from the Phase 3 HARMONi trial showed ivonescimab delayed tumor progression in patients versus chemo alone, the FDA cited that it failed to show a statistically significant improvement in overall survival (OS).

FDA questions survival benefit and population

Ivonescimab, a bispecific antibody, targets two critical proteins: PD-1, which can dampen the immune response to cancer, and VEGF, which helps tumours build a blood supply.

The HARMONi trials are testing ivonescimab in several cancers, including non-small-cell lung cancer, biliary tract cancer, colorectal cancer and urothelial cancer, which most commonly affects the bladder.

Summit disclosed the FDA’s decision about this particular use of the drug on 15 November after receiving a complete response letter from the FDA.

The FDA said the results of the ivonescimab trial for non-small cell lung cancer, as well as showing no statistically significant improvement in overall survival, also showed little difference in the proportion of patients whose tumours responded.

The agency concluded that the evidence was therefore insufficient to support approval for use in patients.

With patients in China making up 60% of the trial participant population and accounting for 93% of the events used to measure progression-free survival, the FDA also questioned how well the progression-free survival results applied to US patients.

Summit later submitted longer-term follow-up that showed a statistically significant survival benefit, with improvements across Western and Asian populations, but the FDA’s letter cited the lack of a statistically significant survival benefit in the final analysis it assessed.

Summit shares plummet

The news of the rejection hit Summit’s market value, its shares closing 16.5% lower on 16 November, their lowest close in two years.

They continued to drop a further 9.7% on Tuesday and 1.6% on Wednesday, closing at $10.50 on 18 November – in total, about 26% below their pre-announcement close.

Shares in Akeso, the Chinese biotech that developed ivonescimab, also closed 17.7% lower in Hong Kong. Summit licensed the drug from Akeso in 2022, securing rights in the US, Canada, Europe and Japan.

Investors are now awaiting results from a separate global phase 3 trial comparing ivonescimab with Merck’s Keytruda (pembrolizumab) as a first treatment for non-small cell lung cancer.

Those results are expected later this year and will give Summit a readout in a larger market than the previously treated group covered by the FDA application.

Analysts expect the decision could also have implications for other drugmakers developing medicines that, like ivonescimab, target both the PD-1 and VEGF

Featured image: sap on AdobeStock

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Rate this content's potential impact on patient outcomes

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this content.